Best Genomics Companies in Houston, United States
The 34 best Genomics companies in Houston, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bellicum.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Houston
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AccessDX Provider of molecular diagnostic solutions and technologies | — | — | Unfunded | 98 | Michael Stewart CEO | Cart FunctionalityWordPressApple iCloud Mail+26 | — | — |
| 2 | AiLife Diagnostics Provider of genetic diagnostic tests and services | — | — | Unfunded | 6 | — | Cart FunctionalityElement UIVue.js+6 | — | — |
| 3 | Albutran Developer of an in-vitro diagnostic platform for cancer and sepsis | — | — | Unfunded | — | Vladimir Muravsky Founder | — | — | — |
| 4 | audubon bioscience Audubon Bioscience is a medicine researcher company. | — | — | Private | 60 | — | WordPressMySQLPHP+24 | — | — |
| 5 | Avance Biosciences Company offering sequencing and PCR based services for assay validation and other clinical trial applications | — | — | Unfunded | 77 77 → 55 (-29%) | Qin Xiang Sr. Director/Co Founder | — | — | — |
| 6 | Baylor Genetics Provider of genetic testing and molecular diagnostics services | — | — | Unfunded | 254 | Tom Caskey Co-Founder | Cart FunctionalityWordPressApple iCloud Mail+32 | — | — |
| 7 | BayPoint Biosystems Predictive diagnostics for ovarian and breast cancer | — | — | Deadpooled | — | James Erickson Founder | — | — | — |
| 8 | Bio Capital Holdings Developer of synthetic yeast and bacteria | — | — | Funding Raised | — | Charles Roe Founder | — | — | — |
Top 12 Genomics companies in Houston
#1
Public · Houston, Texas · founded 2000 · 10 employees$10.3Mraised▾
Developer of therapeutics for the treatment of cancer. The company has developed a proprietary neutral-lipid delivery technology for delivering drugs which include Prexigebersen (Liposomal Grb-2) for patients with AML, CML, breast, and ovarian cancers and BP1002 (Liposomal Bcl2) is being studied for Follicular Lymphoma and other forms of Non-Hodgkin’s Lymphoma.
- Jun 2024Post IPO$4M
- Jan 2019Post IPO$1.7M
- Sep 2018Post IPO$1.5M
- Aug 2013Post IPO—
#2
Series B · Houston, Texas · founded 2018 · 22 employees$33.2Mraised▾
Provider of genomic services for forensic labs. The company enables proprietary genomic biomarkers to analyze the genome profile for investigations and research purposes. They also recover DNA from small samples using amplification. They offer solutions for trait identification and gene relatedness profile by comparing the genome sequence to find ancestry lineage, hair color, height, gene-based relatives, and more.
- Feb 2024Series B$22.1M
- Sep 2021Series B$18M
- May 2020Series A$4.6M
- Apr 2019Grant (prize money)$10K
#3
Seed · Houston, Texas · founded 2013 · 3 employees$1.6Mraised▾
Developer of gene therapies for rare cancers and autoimmune diseases. It offers MiniVectors that are supercoiled DNA minicircles containing only the sequence of interest, which enable the researchers to better transfection efficiencies for cell and gene therapies.
- Aug 2023Conventional Debt—
- Aug 2023Seed$500K
- Jan 2021Seed$1.1M
#4
Funding Raised · Houston, Texas · founded 2006$6.3Mraised▾
Provider of a research and technologies platform in Drosophila transgenesis. It offers services, like P-element insertions, site-specific insertion using the PhiC31 system, MiMIC/RMCE events, and CRISPR gene targeting. They also offer protein tags, point mutations, and null alleles as needed. including cloning of gRNAs and donor cassettes for CRISPR injections, recombineering-based modification of BACs, PCR genotyping of transgenic insertions.
- Sep 2022Grant (prize money)$1.8M
- Sep 2014Grant (prize money)$1.8M
- Jul 2012Grant (prize money)$2.5M
- Jun 2012Grant (prize money)$197.7K
#5
Public · Houston, Texas · founded 2004 · 108 employees$137.5Mraised▾
Bellicum is a developer of T cell therapies for the treatment of cancer and chronic infectious diseases. The company is developing CAR-T and TCR-based T cell therapies. Its drug pipeline consists of BPX-501, an adjunct T-cell therapy for pediatric genetic disease (eg- SCID) and hematologic cancer; BPX-701, a T cell receptor (TCR)-based therapy for the treatment of solid tumours expressing preferentially-expressed antigen in melanoma.
- Sep 2014Series C$94.4M
- Jan 2014Series B$14.7M
- Apr 2013Grant (prize money)$1.2M
- Mar 2012Series B$20M
#6
Funding Raised · Houston, Texas · founded 2013$523.8Kraised▾
Innovating genomic medicine through technology to improve human health and well-being. The company is dedicated to creating innovative technologies to advance genomic medicine. They identify technology needs, create and test ideas, reduce working solutions to practice, and transfer deliverables to production and distribution. Their mission is to transform creative ideas into practical solutions that will improve human health and well being. The staff comprises experts in chemistry, biology, physics, engineering, and systems development. This is a B2B tech company focused on research and development, offering multiple services in the field of genomic medicine.
- Sep 2023Grant (prize money)$299.9K
- Feb 2019Grant (prize money)$223.8K
#7
Acquired · Houston, Texas · founded 2002 · 6001 employees$85Mraised▾
Analytical and clinical lab technologies providing insights and solutions for great science. The company delivers a comprehensive suite of instruments, software, and services to empower laboratories across diverse sectors. These include chemical analysis, life sciences, and diagnostics. The company offers analytical instruments, lab supplies, and instrument repair. It also provides software and informatics solutions for genomics and lab management. The company serves industries like biopharma, cancer research, environmental, food and beverage testing, and clinical diagnostics. The company provides training, consulting, and compliance services. The company's solutions support research, development, and quality control. The company offers e-commerce, order tracking, and technical support. The company focuses on innovation and sustainability.
- Mar 2016PE$80M
- Aug 2011Series A$5M
#8
Seed · Houston, Texas · founded 2018 · 15 employees$4.2Mraised▾
Developer of a non-invasive prenatal diagnostic test. The company is developing a novel technology to capture whole fetal cells present in the maternal blood early in pregnancy and detect different types of genetic abnormalities by using DNA analytic techniques.
- Dec 2021Seed$665K
- Mar 2021Seed$2.4M
- May 2020Seed$1.2M
#9
Funding Raised · Houston, Texas · founded 2006 · 7 employees$6Mraised▾
AM Biotech develops and commercializes X-Aptamers - short strands of chemically modified nucleic acids that bind to targets with high affinity and specificity. X-Aptamers are easier and faster to develop than other affinity reagents such as antibodies or conventional aptamers. AM Biotech offers customers with X-Aptamer development for their targets of choice, in addition to other services such as siRNA synthesis, optimization of existing aptamers, etc.
- Jun 2018Grant (prize money)$304.2K
- Sep 2013Grant (prize money)$1.9M
- Mar 2012Grant (prize money)$180.1K
- Jul 2011Grant (prize money)$156.7K
#10
Acqui-Hired · Houston, Texas · founded 1999$6Mraised▾
Bacterial Barcodes developed DiversiLab®, an automated rapid strain typing platform that uses rep-PCR technology to provide standardized, reproducible DNA fingerprinting and analysis of bacterial and fungal samples for complete isolate characterization. This is used to track hospital-acquired infections and environmental control and product safety. The company was acquired by bioMérieux, which works in the field of in-vitro diagnostics.
- Feb 2003Series C$6M
#11
Series A · Houston, Texas · founded 2013 · 6 employees$3.7Mraised▾
Provider of clinical intelligence platform for precision oncology and immunotherapy. The platform facilitates clinical decision support through a rapid learning system. It automates molecular knowledge aggregation, allowing organizations to augment their offerings. The technology scales to provide evidence-based recommendations, supporting high patient volume. It delivers personalized results through a biomedical ontology with natural language processing and machine learning. The automated technology reduces manually intensive processes associated with molecular recommendations. The system integrates to complement existing workflows.
- Aug 2014Series A$593K
- 2014Series A$3.1M
#12
Funding Raised · Houston, Texas · founded 2004 · 18 employees$572.4Kraised▾
Provider of products and services for genomics and proteomics research. Its technologies include VariantPro Targeted Sequencing Technology - a multiplex PCR-based targeted sequencing method and µParaflo Microarray Technology for oligonucleotide and peptide synthesis. Its genomics, transcriptomics, and proteomics products and services are based on high-throughput sequencing technology and its flexible µParaflo custom microarrays including services for nucleic acid/protein profiling and functional analysis, biomarker-discovery, and novel drug screening.
- Jul 2009Grant (prize money)$572.4K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics in Houston is moving
A read on the academic research around Bioinformatics in Houston — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 103 papers.
- The University of Texas Health Science Center at Houston63
- University of Houston16
- Houston Methodist16
- Houston Fertility Institute4
- Houston Institute for Clinical Research3
- Gene1→6
- Disease7
- DNA methylation4
- Cell3
- Epigenetics3
- Breast cancer3
- Obesity2
- Biosensor1
- Protein detection1
- Sensitivity (control systems)1
- Continuous monitoring1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.